Cavitation Technologies, INC

James Fuller voluntarily resigned from the Board of Directors of Cavitation Technologies, Inc. effective August 22, 2024, for personal reasons.

Cavitation Technologies, Inc. reported a substantial net loss of $734,000 for the six months ended December 31, 2025, driven by a sharp decline in revenue and increased operating expenses, raising significant going concern doubts.

Cavitation Technologies, Inc. reported increased net losses and a significant cash burn, raising substantial doubt about its ability to continue as a going concern.

Cavitation Technologies reports a net income of $122,000 for the nine months ended March 31, 2025, despite a significant decrease in revenue due to a patent assignment with Desmet.

Cavitation Technologies, Inc. reports a net income of $352,000 for the six months ended December 31, 2024, primarily due to a gain on patent assignment to Desmet Ballestra.

Cavitation Technologies reports a net loss of $227,000 for the quarter ended September 30, 2024, while also highlighting a significant patent assignment agreement with Desmet and a strategic shift towards new markets.

Cavitation Technologies, Inc. saw a significant increase in revenue and a return to profitability in Q3 2024, driven by a new licensing agreement, but concerns about the company's ability to continue as a going concern persist.

Cavitation Technologies, Inc. reported a net loss of $113,000 for fiscal year 2025, a significant decline from the prior year's profit, as it shifts focus to new ventures in water treatment and alcoholic beverages.

Cavitation Technologies, Inc. achieved a net income of $439,000 in fiscal year 2024, a significant turnaround from a net loss in the previous year, primarily due to increased sales of its Nano Reactor systems.